ATEZOLIZUMAB - BEVACIZUMAB in the Treatment Hepatocellular Carcinoma Inoperable or (HEPATOFIT)

Regional University Hospital Center (CHRU)

Status: Unknown

Conditions: Advanced Hepatocellular Carcinoma

Study type: Observational

Funder types: Other

Identifiers

NCT04730388

29BRC20.0325

Details and patient eligibility

About

Evaluation of the efficacy and safety of the combination ATEZOLIZUMAB - BEVACIZUMAB in the treatment of locally advanced inoperable or metastatic hepatocellular carcinoma in Finistère

Full description

Patients treated by ATEZOLIZUMAB and BEVACIZUMAB for an Advanced hepatocellular carcinoma will be followed to observed their safety and the efficacy of this treatment, and to identify prongnosis factors

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• hepatocellular carcinoma locally advanced or metastatic, non able to be resectable, with no prior systemic treatment
• Child Pugh A and ECOG 0 or 1
• upper digestiuve endoscopy less than 6 months, if esophageal varcices : must be treated
• non eligible to receive a locoregional therpay or progressive after this kinf of treatment
• with informed consent

Exclusion criteria

• refuse to participate
• under legal protection
• exclusion criteria from the tempory utilisation authorization